Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNIA
2022-501351-82-00Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM), polymyositis (PM) and antisynthetase syndrome (ASSD) comparing Enpatoran + standard of care with Placebo + standard of care (2 arms). Started May 2023; status: completed.
02
Drugs
enpatoran
03
Conditions
dermatomyositis (DM)polymyositis (PM)antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on 2022-501351-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501351-82-00.